Grifols, S.A., GRFS is in the exchange NASDAQ and its industry is Biotechnology in the sector of Healthcare. Based in Spain, Grifols, S.A., GRFS has a market cap of 23180.4. Since its IPO date on the 6/2/2011, Grifols, S.A., GRFS performance year to date is 5.43%. Today Grifols, S.A., GRFS has gained 1.62%, with a current price of 16.92.
Ownership of the company is *TBA for insider ownership while institutional ownership is *TBA. The management of the company have seen the company have a payout ratio of *TBA. Return of assets are at *TBA, with return on investment at *TBA.
In terms of debt levels and profit levels, Grifols, S.A., GRFS is seeing a long-term debt/equity of *TBA. While Total debt/equity is *TBA. With a profit margin of *TBA, this is combined with a gross margin of *TBA, and operating margin of *TBA. Grifols, S.A. ability to meet debt levels, with a current ratio of *TBA, while the quick ratio is *TBA.
For the last year Grifols, S.A., GRFS has seen a EPS growth of 3.00%. A performance for the year of 12.11%. The 52-week high is -4.27%, and the 52-week low is 21.39%. The average volume for Grifols, S.A., GRFS is 654648.
With a target price of 15, can Grifols, S.A., GRFS reach this target? Looking at the value indicators of Grifols, S.A., GRFS. Grifols, S.A. has a P/E of 39.35 and a forward P/E of 14.84. Perhaps the more useful indicator than P/E, is PEG which has a value of 2.62. Grifols, S.A. also has a P/S and a P/B of 5.28 and 6.38 respectively. For P/cash, Grifols, S.A. has a value of *TBA, while it is *TBA for P/free cash flow.
At the current price of 16.92, Grifols, S.A. has a dividend yield of 3.07%. We see a return on equity of *TBA.
Looking more long-term Grifols, S.A., is projected to get an EPS growth for the next five years of 15.00%. In the short-term an EPS growth of 10.70% in the next year is forecasted. This is after a EPS growth of 3.00% for this year and for the last five years a 39.67% growth has been seen.